Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125223211 | 12522321 | 1 | I | 20110820 | 20160624 | 20160701 | 20160701 | EXP | FR-SA-2016SA119312 | AVENTIS | 73.00 | YR | E | M | Y | 0.00000 | 20160701 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125223211 | 12522321 | 1 | PS | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | UNK | 21081 | 26 | IU | QD | |||||||
| 125223211 | 12522321 | 2 | SS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | DOSE: MORNING AND?NOON 6 IU;?EVENING 16 TO?18 IU | UNK | 0 | TID | ||||||||
| 125223211 | 12522321 | 3 | C | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | STRENGTH: 75MG | 0 | POWDER FOR ORAL SOLUTION | |||||||||
| 125223211 | 12522321 | 4 | C | LOXEN | NICARDIPINE HYDROCHLORIDE | 1 | Oral | STRENGTH: 50MG | 0 | ||||||||||
| 125223211 | 12522321 | 5 | C | COOLMETEC | HYDROCHLOROTHIAZIDEOLMESARTAN MEDOXOMIL | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 6 | C | ATENOLOL. | ATENOLOL | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 7 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 8 | C | IXPRIM | ACETAMINOPHENTRAMADOL HYDROCHLORIDE | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 9 | C | RIVOTRIL | CLONAZEPAM | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 10 | C | FLUVASTATIN | FLUVASTATIN SODIUM | 1 | Oral | 0 | |||||||||||
| 125223211 | 12522321 | 11 | C | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125223211 | 12522321 | 1 | Type 1 diabetes mellitus |
| 125223211 | 12522321 | 2 | Type 1 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125223211 | 12522321 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125223211 | 12522321 | Hyperhidrosis | |
| 125223211 | 12522321 | Hypoglycaemic coma | |
| 125223211 | 12522321 | Muscle contracture | |
| 125223211 | 12522321 | Pallor |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |